CARRIE BRODMERKEL, Ph.D.
Carrie Brodmerkel, Ph.D. is Portfolio Leader for the Janssen BioTherapeutics (JBIO), Janssen Research & Development organization. In this role, Carrie oversees the strategic direction of the company’s biotherapeutics science and portfolio, and leverages her significant scientific and leadership experience to mentor JBIO Team Leaders.
She serves on the JBIO Leadership Team and is based at the Janssen R&D Spring House, PA, research hub.
Previously, Carrie led the Biomarker team within the Immunology Therapeutic Area, Janssen R&D, where she was responsible for strategic and operational implementation of translational efforts in support of asset development for disease interception, early disease intervention and treatment of established disease across rheumatology, dermatology and gastroenterology.
Carrie joined Johnson & Johnson in 2005 and since then has contributed significantly to building the Immunology TA’s molecular disease expertise and computational capabilities. In 2010, she was awarded the Johnson Medal for her translational work in the development of STELARA® (ustekinumab) for moderate to severe psoriasis. In her early career, Carrie worked in pre-clinical drug discovery utilizing in vivo pharmacological modeling of immune diseases in her roles at Dupont Pharmaceuticals and Incyte Corporation.
Carrie earned her Ph.D. in Pathology at Albert Einstein College of Medicine studying chemokines and chemokine receptors and their role in the neuroinflammatory processes of multiple sclerosis and HIV encephalopathy. She completed a post-doctoral fellowship at the University of Pennsylvania, studying chemokine receptors and their role in HIV entry.